Achalasia Microcephaly Syndrome
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Achalasia Microcephaly Syndrome

What is the definition of Achalasia Microcephaly Syndrome?
Achalasia microcephaly syndrome is an extremely rare genetic syndrome that appears in infants and is characterized by microcephaly (abnormally small head), intellectual disability, achalasia (esophageal dysfunction), and failure to thrive (growth and development delay).
What are the symptoms of Achalasia Microcephaly Syndrome?
Symptoms of achalasia microcephaly syndrome include an abnormally small skull (microcephaly), intellectual disability, the presence of eye folds, crossed eyes, large ears, prominent nose, large lower jaw (mandibular prognathia), excessive hairiness (hirsutism), coughing, aspiration, vomiting, difficulty swallowing, and esophageal dysfunction (achalasia).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Achalasia Microcephaly Syndrome?
While there is no cure for achalasia microcephaly syndrome, treatment focuses on alleviating symptoms and supportive care and may include surgery to help alleviate esophageal dysfunction.
Who are the top Achalasia Microcephaly Syndrome Local Doctors?
Elite in Achalasia Microcephaly Syndrome
Pediatrics | Neurology | Medical Genetics
Elite in Achalasia Microcephaly Syndrome
Pediatrics | Neurology | Medical Genetics
Referral may be required

M Health Fairview Explorer Pediatric Specialty Clinic

2450 Riverside Avenue, Floor 12, 
Minneapolis, MN 
Experience:
48+ years
Languages Spoken:
English
Accepting New Patients

William Dobyns is a Pediatrics specialist and a Neurologist practicing medicine in Minneapolis, Minnesota. He has been practicing medicine for over 48 years. Dr. Dobyns is rated as an Elite provider by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Increased Head Circumference, Lissencephaly, Cerebellar Hypoplasia, and Cortical Dysplasia. Dr. Dobyns is board certified in Clinical Genetics And Genomics: American Board Of Medical Genetics And Genomics, 1987. Dr. Dobyns is currently accepting new patients.

Elite in Achalasia Microcephaly Syndrome
Elite in Achalasia Microcephaly Syndrome
Referral may be required
Erlangen, BY, DE 

Heinrich Sticht practices practicing medicine in Erlangen, Germany. Mr. Sticht is rated as an Elite expert by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Achalasia Microcephaly Syndrome, Microcephaly, Cytomegalovirus Infection, and Cortical Dysplasia.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Achalasia Microcephaly Syndrome
Medical Genetics
Elite in Achalasia Microcephaly Syndrome
Medical Genetics
Referral may be required

Nemours Children's Hospital, Delaware

1600 Rockland Road, 
Wilmington, DE 
Languages Spoken:
English
Accepting New Patients

Michael Bober is a Medical Genetics provider practicing medicine in Wilmington, Delaware. Dr. Bober is rated as an Elite provider by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 69 other conditions, according to our data. His clinical expertise encompasses Microcephalic Osteodysplastic Primordial Dwarfism Type 2 (MOPD2), Microcephalic Osteodysplastic Primordial Dwarfism Type 1 (MOPD1), Achondroplasia, Osteotomy, and Adenoidectomy. Dr. Bober is board certified in American Board Of Medical Genetics And Genomics. Dr. Bober is currently accepting new patients.

What are the latest Achalasia Microcephaly Syndrome Clinical Trials?
A Phase 1/2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients With Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene.

Summary: MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Second...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Investigations of Individuals With MEHMO Syndrome or eIF2-Pathway Related Conditions

Summary: This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A m...